



19 April 2013

ASX RELEASE

Novogen Director Steps Down

Novogen Board member, Josiah Austin, today announced his resignation as non-executive director. Josiah is Novogen's largest shareholder and has been a director for 4 years. Josiah cited as a reason the practical difficulties of being US-based and having to attend monthly Board meetings in Australia.

Dr Graham Kelly, Novogen Chairman and CEO, said today, "I asked Josiah to stay on when Triaxial merged with Novogen late last year to provide some continuity. Now with the new Board functioning smoothly, he believes that it is time for him to go and avoid the rigours and expense of a monthly plane trip."

"Josiah has been a true friend to Novogen and has indicated that he intends to maintain his significant shareholding position."

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The Company's inaugural drug candidate is CS-6.

About CS-6

CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells. CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.

About Cancer Stem Cells

Cancer stem cells (CSC) (or tumour-initiating cells) are believed to be a subpopulation of cells within many types of cancer that are responsible for driving the growth and spread of the cancer. CSC typically are resistant to radiotherapy and chemotherapy and are thought to be responsible for cancer recurrence following therapy. Targeting CSC is a new direction in oncology drug development as a means of preventing cancer recurrence.



Further information

Contact Dr Graham Kelly, Chief Executive Officer.

M: (61) 0459 200 095

E: Graham.Kelly@novogen.com

Please note that the Company currently is relocating offices and that the original phone numbers no longer are in use. New contact details will be available shortly.

Further information is available on the Company's web site, www.novogen.com